• CME

  • Pathogenesis, Diagnosis, and Management of HIV-Associate Lipodystrophy: Applying the Patient's Perspective to Practice

  • Author(s)/Faculty: W. David Hardy; Andrew Carr, MD, MBBS, FRACP, FRCPA; Paul E. Sax, MD
    Source: Healio Infectious Diseases - IDN Education Lab
    Type: Monograph Articles/Items: 6
    Release Date: 2/1/2012 Expiration Date: 2/28/2013
    Credit Type: CME Number of Credit(s): 1.25
    Cost: Free Provider: Vindico Medical Education
  • HIV-associated lipodystrophy has many adverse health effects, enhancing the importance of identifying affected patients and knowing appropriate management options. Lipodystrophy results in deleterious cosmetic effects that can reduce patient’s quality of life, and potentially lead to reduced antiretroviral therapy adherence. Many patients have increased waist circumference concomitant with the loss of subcutaneous fat, which can be a predictor of increased risk of coronary artery disease and death. Over the last decade marked advancements in management have been made, resulting in the first available treatment for lipodystrophy.

Sponsorship Statement: This continuing medical education activity is jointly sponsored by Vindico Medical Education and

Support Statement: This activity is supported by an educational grant from

Target Audience: The intended audience for the activities is infectious disease specialists and other healthcare professionals involved in the treatment of patients with HIV.

Learning Objectives: Upon completion of this activity, participants should be able to:

  1. Assess the pathogenesis of lipodystrophy in HIV-infected patients by reviewing the effects of antiretroviral medications, HIV itself, as well as genetic and other host factors.
  2. Implement diagnostic methodologies into practice that assess patients early for signs and symptoms of HIV-associated lipodystrophy.
  3. Apply evidence-based medicine to effectively treat and manage HIV-associated lipodystrophy to improve the physiological and psychological aspects of the disease as well as increase patient adherence to therapeutic regimens,

Course Chair:
W. David Hardy, MD
Director, Division of Infectious Diseases
Cedars-Sinai Medical Center
Associate Professor of Medicine-in-Residence
David Geffen School of Medicine at UCLA
Editorial Board Member
INFECTIOUS DISEASE NEWS
Los Angeles, CA

Faculty:
Andrew Carr, MD, MBBS, FRACP, FRCPA
Head
HIV, Immunology and Infectious Diseases Unit Head Clinical Research Program Centre for Applied Medical Research St Vincent's Hospital and Professor of Medicine University of New South Wales
Sydney, Australia

Paul E. Sax, MD
Clinical Director, HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Cambridge, MA

Accreditation:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vindico Medical Education and INFECTIOUS DISEASE NEWS®. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, February 1, 2012 to February 28, 2013.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Planning Committee and Faculty:
W. David Hardy, MD
Andrew Carr, MBBS, MD, FRACP, FRCPA
Paul E. Sax, MD

External Reviewer:
C. Bradley Hare, MD

Medical Writer:
Valerie Zimmerman, PhD

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty members report the following relationship(s):
W. David Hardy, MD
Consulting Fees: Gilead, Viiv, Tibotec, GlaxoSmithKline
Contract Research: Gilead, Viiv, GlaxoSmithKline, Pfizer, Bionor Pharma
Ownership Interest: Merck & Co

Andrew Carr, MD, MBBS, FRACP, FRCPA
Research funding: Baxter, GlaxoSmithKline/ViiV Healthcare, Merck and Pfizer
Consultancy fees: Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Merck and Roche
Lecture and travel sponsorships: Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, and Merck
Advisory Boards: Abbott, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Merck and Roche

Paul E. Sax, MD
Consultant: Abbott, BMS, Gilead, GSK, Merck, Tibotec
Grant Support: BMS, Glilead, Merck, GSK, Tibotec

External Reviewer reports the following relationship(s):
C. Bradley Hare, MD
Consulting Fees: Viiv, Gilead, Merck, BMS, Janssen
Fees for Non-CME Services: Viiv, Gilead, Merck, BMS, Janssen

Medical Writer reports the following relationship(s):
Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Vindico Medical Education and INFECTIOUS DISEASE NEWS® staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-384-6680. Printed in the USA. Copyright © 2012 SLACK Incorporated®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and INFECTIOUS DISEASE NEWS® continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and INFECTIOUS DISEASE NEWS®. Neither Vindico Medical Education and INFECTIOUS DISEASE NEWS®, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.